click below
click below
Normal Size Small Size show me how
BDK: ENDOCRINE 1
25-26 LIST
| GENERIC | BRAND | CATEGORY | INDICATION | SIDE EFFECTS | BOXED WARNINGS | NOTES |
|---|---|---|---|---|---|---|
| Metformin | Fortamet, Glumetza | Biguanide | Type 2 DM, PCOS | diarrhea, nausea, vomiting, Vitamin B12 deficiency | lactic acidosis | CI with eGFR <30 |
| Sitagliptin | Januvia, Zituvio | Dipeptidyl peptidase (DPP-4) inhibitor | Type 2 DM | nasopharyngitis | ||
| Empagliflozin | Jardiance | Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | Type 2 DM, HF, CKD | genital mycotic infections, UTI | ||
| Dapagliflozin | Farxiga | Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | Type 2 DM, HF, CKD | genital mycotic infections, UTI | ||
| Glimepiride | Amaryl | Sulfonylurea | Type 2 DM | hypoglycemia, weight gain | ||
| Glipizide | Glucotrol/XL | Sulfonylurea | Type 2 DM | hypoglycemia, weight gain | ||
| Pioglitazone | Actos | Thiazolidinedione | Type 2 DM | peripheral edema, weight gain, upper respiratory tract infection; increased risk of fractures and bladder cancer | may exacerbate congestive heart failure and CI in NYHA Class III and IV | |
| Dulaglutide | Trulicity | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM | nausea, vomiting, diarrhea, pancreatitis | may increase risk of thyroid c-cell tumor | |
| Liraglutide | Victoza, Saxenda | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM, chronic weight management | nausea, vomiting, diarrhea, constipation, pancreatitis | may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer | |
| Semaglutide | SQ: Ozempic, Wegovy PO: Rybelsus | Glucagon-like peptide-1 (GLP-1) receptor agonist | Type 2 DM, chronic weight management | nausea, vomiting, diarrhea, constipation, pancreatitis | may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer | |
| Tirzepatide | Mounjaro, Zepbound | Dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist | Type 2 DM, chronic weight management | nausea, vomiting, diarrhea, constipation, increased heart rate, pancreatitis | may increase risk of thyroid c-cell tumor | |
| insulin glargine | Lantus, Toujeo, Basaglar | Insulin, long acting | Type 1 DM, type 2 DM | hypoglycemia, weight gain | ||
| insulin NPH | Humulin N, Novolin N | Insulin, intermediate acting | Type 1 DM, type 2 DM | hypoglycemia, weight gain | ||
| insulin aspart | Novolog | Insulin, rapid acting | Type 1 DM, type 2 DM | hypoglycemia, weight gain | ||
| insulin lispro | Humalog | Insulin, rapid acting | Type 1 DM, type 2 DM | hypoglycemia, weight gain | ||
| insulin regular | Humulin R, Novolin R | Insulin, short-acting | Type 1 DM, type 2 DM, DKA | hypoglycemia, weight gain |